Sojournix Announces Initiation of Phase 2 Clinical Trial of SJX-653, a Novel Selective NK3 Antagonist for Menopausal Hot Flashes
WALTHAM, Mass. , February 24 /Businesswire/ - Sojournix announces initiation of Phase 2 clinical trial of SJX-653, a novel selective NK3 antagonist for menopausal hot flashes.